Industry Report | 2024
The cannabis industry entered 2024 at an inflection point. A decade of rapid legalization has left operators navigating a regulatory patchwork that varies state by state, a tax burden that makes black market competition increasingly rational, and capital markets that treat the industry as too risky for traditional financing while too fragmented for institutional investment.
This report covers every dimension of that reality — without softening the picture. The state of the cannabis industry is complex. It rewards operators who understand the policy environment, not just the plant.
What This Report Covers
The 2024 State of the Cannabis Industry is 114 pages of data, analysis, and unvarnished assessment. Nine major sections: market overview, federal policy, state regulatory landscape, social equity programs, organized labor, capital markets, M&A activity, emerging categories, and the 2025 outlook.
Key Findings
Social equity programs continue to fail — not because of lack of intent, but because the structural requirements disqualify the very people they’re designed to help. Prior cannabis convictions, low-income thresholds, and 51% ownership mandates combine to ensure that the most qualified candidates are screened out. The program design is the problem.
Organized labor’s relationship with cannabis operators has shifted. The unions that spent political capital legitimizing the industry in its early years have been replaced, in many markets, by a second generation with no institutional memory of that work — and no reluctance to use leverage against the operators who benefited from it. The hierarchy of union interests runs: union survival first, dues-paying members second, everything else a distant third.
Federal rescheduling from Schedule I to Schedule III is the most significant federal policy shift since legalization began — and its commercial implications are widely misunderstood. The 280E tax relief alone changes the P&L structure for licensed operators. But rescheduling is not legalization, and the downstream effects on state regulatory frameworks are not straightforward.
The MSO consolidation wave produced scale without brand equity or operational efficiency. The distress resulting from that miscalculation is creating acquisition opportunities for buyers who can operate, not just capitalize. The next cycle will reward operators over financiers.
Psychedelics are on a 5–7 year trajectory toward regulated commercial markets, following the same legislative playbook as cannabis — with a more receptive regulatory environment and a more sympathetic clinical profile. The adjacent opportunity is real and underpriced.
The Bottom Line
The cannabis industry’s first decade was about legalization. The second decade will be about consolidation, efficiency, and institutional capital finding its footing in an industry that no longer needs to prove it’s legitimate — it needs to prove it’s investable.
This report is the most comprehensive independent assessment of where the industry stands and where it’s going. It is written for operators, investors, regulators, and anyone serious about understanding cannabis as a business.
FULL REPORT
Request the Complete 114-Page Report
The summary above covers key findings. The full report includes detailed data, state-by-state regulatory breakdowns, capital markets analysis, M&A activity, and complete sections on organized labor and social equity.